Summit leverages a partnership with Akeso Inc. to advance ivonescimab development across multiple tumor types, with three Phase III trials (HARMONi, HARMONi-3, HARMONi-7) underway in the US, Canada, Europe and other territories. The company benefits from Akeso's established clinical data from China and positions itself as a leader in bringing innovative oncology therapies to unmet medical needs.
Cyborg Score Rationale
Summit demonstrates strong execution with multiple Phase III trials, FDA acceptance for BLA filing, clinical collaborations with major pharma (GSK), and a well-funded balance sheet. However, the company is pre-revenue in its lead indication with binary regulatory risk and dependency on external partnership.
Top Insights
Ivonescimab demonstrates dual mechanism targeting PD-1 and VEGF via cooperative binding, addressing multiple pathways in immuno-oncology
Over 3,000 patients treated globally with ivonescimab; FDA accepted BLA submission indicates significant regulatory progress momentum
Strategic partnership with Akeso provides access to Phase III data from China where ivonescimab is already approved, accelerating global development
Company carries significant clinical and regulatory execution risk with no product revenue; success dependent on Phase III trial readouts and FDA approval
Named Competitors
Keytruda — Anti-PD-1 checkpoint inhibitor
Opdivo — Anti-PD-1 checkpoint inhibitor
Libtayo — Anti-PD-L1 checkpoint inhibitor
Tecentriq — Anti-PD-L1 checkpoint inhibitor
Recent Developments
(Jan 2026) FDA acceptance of Biologics License Application for ivonescimab filing
(Oct 2025) ESMO data update announced with Phase III HARMONi-6 results from China-sponsored trials
(2025) Clinical trial collaboration with GSK to evaluate ivonescimab in combination studies
Open the full interactive Summit Therapeutics Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.